ReviewPharmacogenomics2012
Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
Review in Pharmacogenomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials.Frontiers in oncology · 2021Pooled it
- Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Pooled it
- The germline mutational landscape of BRCA1 and BRCA2 in Brazil.Scientific reports · 2018Trial
- Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer.Cancer discovery · 2025Article
- Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.The Annals of pharmacotherapy · 2023Article
- The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer.International journal of molecular sciences · 2022Review
- Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome.Cancers · 2022Review
- A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.Current oncology (Toronto, Ont.) · 2022Article
- The current state of molecular profiling in gastrointestinal malignancies.Biology direct · 2022Review
- Intratumoral expression analysis reveals that OX40 and TIM-3 are prominently expressed and have variable associations with clinical outcomes in high grade serous ovarian cancer.Oncology letters · 2022Article
- Review
- The BRCA Gene in Epithelial Ovarian Cancer.Cancers · 2022Review
- Integration of Genomic Profiling and Organoid Development in Precision Oncology.International journal of molecular sciences · 2021Review
- Review
- Transcriptome Patterns ofInternational journal of molecular sciences · 2021Article
- Epithelial/mesenchymal heterogeneity of high-grade serous ovarian carcinoma samples correlates with miRNA let-7 levels and predicts tumor growth and metastasis.Molecular oncology · 2020Article
- Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.Scientific reports · 2020Article
- Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.Molecular genetics & genomic medicine · 2019Article
- Tailoring Ovarian Cancer Treatment: Implications ofCancers · 2019Review
- Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.Genetics and molecular biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
A key function of BRCA1 and BRCA2 is the participation in dsDNAbreak repair via homologous recombination. BRCA1 and BRCA2 mutations, which occur in most hereditary ovarian cancers (OCs) and approximately 10% of all OC cases, are associated with defects in homologous recombination and genomic instability, a phenotype termed 'BRCAness'. The clinical effects of BRCA1 and BRCA2 mutations have commonly been analyzed together; however, it is becoming increasingly apparent that these mutations do not have the same effects in OC. Recently, three major reports highlighted the unequal clinical characteristics of OCs with BRCA1 and BRCA2 mutations. All studies demonstrated that BRCA2-mutated patients are associated with better survival and therapeutic response than BRCA1-mutated and wild-type patients with serous OC. The differing prognostic effects of the BRCA2 and BRCA1 mutations is likely due to differing roles of BRCA1 and BRCA2 in homologous recombination repair and a stronger association between the BRCA2 mutation and a hypermutator phenotype. These new findings have potentially important implications for clinical management of patients with serous OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.